Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Richard A, Koup"'
Autor:
Cynthia L Gay, Katherine S James, Marina Tuyishime, Shane D Falcinelli, Sarah B Joseph, Matthew J Moeser, Brigitte Allard, Jennifer L Kirchherr, Matthew Clohosey, Samuel L M Raines, David C Montefiori, Xiaoying Shen, Robert J Gorelick, Lucio Gama, Adrian B McDermott, Richard A Koup, John R Mascola, Michelle Floris-Moore, JoAnn D Kuruc, Guido Ferrari, Joseph J Eron, Nancie M Archin, David M Margolis
Publikováno v:
J Infect Dis
We tested the combination of a broadly neutralizing HIV antibody with the latency reversal agent vorinostat (VOR). Eight participants received 2 month-long cycles of VRC07-523LS with VOR. Low-level viremia, resting CD4+ T-cell–associated HIV RNA (r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6faf11d8516c4ae68e516f570f2bdba2
https://europepmc.org/articles/PMC8889279/
https://europepmc.org/articles/PMC8889279/
Autor:
Jason Hataye, Zhi Yong Yang, Nicole A. Doria-Rose, John R. Mascola, Giulia Fabozzi, Hui Li, Tongqing Zhou, Wei Shi, Kylie March, Brandon F. Keele, George M. Shaw, Joseph P. Casazza, Kathryn E. Foulds, Joana Dias, Wanwisa Promsote, Gary J. Nabel, Michelle D. Cully, Richard A. Koup, Xuejun Chen, Amarendra Pegu, Ling Xu, Ronnie Wei, Hui Geng, Cuiping Liu, Amy Noe, Jeffrey D. Lifson, Cassandra G. Almasri, Ercole Rao, Constantinos Petrovas, Mangaiarkarasi Asokan, John-Paul Todd, Krisha McKee, Christine M. Fennessey, Stephen D. Schmidt, Eun Sung Yang, Megan E. DeMouth, Keyun Wang, Shing-Fen Kao
Publikováno v:
SSRN Electronic Journal.
Broadly neutralizing antibodies (bNAbs) represent an alternative to drug therapy for the treatment of HIV-1 infection. Immunotherapy with single bNAbs often leads to emergence of escape variants, suggesting a potential benefit of combination bNAb the
Autor:
Pablo Tebas, Robert F. Siliciano, Mohamed Abdel-Mohsen, Jun Lai, E. Turner Overton, Kevin McCormick, James A. Hoxie, Randall Tressler, Scott Sherrill-Mix, Janet M. Siliciano, Jonathan Z. Li, D. Brenda Salantes, Richard A. Koup, Tuhina Srivastava, Yu Zheng, Felicity Mampe, Gerald H. Learn, Frederic D. Bushman, Subul A. Beg, Katharine J. Bar
Publikováno v:
Journal of Clinical Investigation. 128:3102-3115
BACKGROUND. The effect of a brief analytical treatment interruption (ATI) on the HIV-1 latent reservoir of individuals who initiate antiretroviral therapy (ART) during chronic infection is unknown. METHODS. We evaluated the impact of transient viremi
Autor:
Jeffrey D. Lifson, John R. Mascola, Sean P. O’Brien, Theodora Hatziioannou, Paul D. Bieniasz, Jason Gorman, Brandon F. Keele, George M. Shaw, Gregory Q. Del Prete, Richard A. Koup, Taina T. Immonen, Adrienne E. Swanstrom, Christine M. Fennessey, Amarendra Pegu, Kathryn E. Foulds, Nicole A. Doria-Rose, Peter D. Kwong, Sung-Youl Ko, Mario Roederer, Carolyn Williamson, Stephen D. Schmidt, Hui Li
Publikováno v:
PLoS Pathogens
PLoS Pathogens, Vol 15, Iss 4, p e1007632 (2019)
PLoS Pathogens, Vol 15, Iss 4, p e1007632 (2019)
Chimeric Simian-Human Immunodeficiency Viruses (SHIVs) are an important tool for evaluating anti-HIV Env interventions in nonhuman primate (NHP) models. However, most unadapted SHIVs do not replicate well in vivo limiting their utility. Furthermore,
Autor:
Patrick Younan, Mathieu Iampietro, Andrew Nishida, Palaniappan Ramanathan, Rodrigo I. Santos, Mukta Dutta, Ndongala Michel Lubaki, Richard A. Koup, Michael G. Katze, Alexander Bukreyev, John T. Patton
Publikováno v:
mBio
mBio, Vol 8, Iss 5 (2017)
mBio, Vol 8, Iss 5, p e00845-17 (2017)
mBio, Vol 8, Iss 5 (2017)
mBio, Vol 8, Iss 5, p e00845-17 (2017)
Ebola virus (EBOV) disease (EVD) results from an exacerbated immunological response that is highlighted by a burst in the production of inflammatory mediators known as a “cytokine storm.” Previous reports have suggested that nonspecific activatio
Autor:
Richard A. Koup, Amanda L. Brinkman, Dan H. Barouch, Brandon F. Keele, Boris Julg, Stephen D. Schmidt, Xuejun Chen, John R. Mascola, Jinyan Liu, Katherine Molloy, Shanell Mojta, Michael S. Seaman, Katherine Callow, Abishek Chandrashekar, Jinghe Huang, Peter Abbink, Keyun Wang, Amarendra Pegu, Mark Connors
Publikováno v:
Journal of Virology. 91
Passive immunotherapy against HIV-1 will most likely require broadly neutralizing antibodies (bnAbs) with maximum breadth and potency to ensure therapeutic efficacy. Recently, the novel CD4 binding site antibody N6 demonstrated extraordinary neutrali
Autor:
S. Munir Alam, Guido Ferrari, Thomas N. Denny, Stephen D. Schmidt, Mark K. Louder, Brandy M. Ward, Norman L. Letvin, Hugh C. Welles, Rosemarie D. Mason, Ling Shen, Celia C. LaBranche, Raphael Gottardo, Kathryn E. Foulds, Kelly E. Seaton, Martha Nason, Robert T. Bailer, Robert A. Seder, Will Fischer, Linh Mach, Mario Roederer, John R. Mascola, Georgia D. Tomaras, Bette T. Korber, Srinivas S. Rao, John Paul Todd, Brandon F. Keele, Adam P. Buzby, Gary J. Nabel, Richard A. Koup, Zhi-Yong Yang, David C. Montefiori, Wenjuan Gu
Publikováno v:
Nature
A major challenge for the development of a highly effective AIDS vaccine is the identification of mechanisms of protective immunity. To address this question, we used a nonhuman primate challenge model with simian immunodeficiency virus (SIV). We sho
Autor:
Kapil K. Saharia, Richard A. Koup
Publikováno v:
Cell. 155(3):505-514
During HIV infection, the timing of opportunistic infections is not always associated with severity of CD4 T cell depletion, and different opportunistic pathogens reactivate at different CD4 T cell thresholds. Here, we examine how differences in the
Autor:
Rupert Kaul, Connie J. Kim, Susan Moir, Cecilia T. Costiniuk, Gabor Kandel, Joseph P. Casazza, Erika Benko, Tae-Wook Chun, Colin Kovacs, Mario A. Ostrowski, Richard A. Koup, Jana Blazkova, J. Shawn Justement, Claire W. Hallahan, Anthony S. Fauci, Danielle Murray
Publikováno v:
The Journal of Infectious Diseases. 208:1443-1447
Elite controllers suppress human immunodeficiency virus (HIV) viremia to below the limit of detection in the absence of antiretroviral therapy (ART). However, precise frequencies of CD4(+) T cells carrying replication-competent HIV and/or the dynamic
Autor:
Julie E. Ledgerwood, Raphael Gottardo, David Price, Emily C. Smith, Robert T. Bailer, Deborah Persaud, Frank Maldarelli, Emma Gostick, Charla A. Andrews, Ingelise J. Gordon, Barney S. Graham, Martha Nason, Mario Roederer, Ann Wiegand, Selorm Adzaku, Mary F. Kearney, David R. Ambrozak, Richard A. Koup, Joseph P. Casazza, Kathryn Bowman, Mary E. Enama, Carrie Ziemniak
Publikováno v:
The Journal of Infectious Diseases. 207:1829-1840
Background. The licensing of herpes zoster vaccine has demonstrated that therapeutic vaccination can help control chronic viral infection. Unfortunately, human trials of immunodeficiency virus (HIV) vaccine have shown only marginal efficacy.Methods.